GSK plc (LSE/NYSE: GSK) today announced positive results from its pivotal Phase III clinical trial program for bepirovirsen. This investigational treatment could redefine the standard [Read More…]
In its first major move of 2026, Amgen (NASDAQ: AMGN) has announced the acquisition of Dark Blue Therapeutics Ltd., a privately held U.K. biotech specializing [Read More…]
Novo Nordisk has officially launched the Wegovy® pill, the first-ever oral GLP-1 medication for weight management in adults. Following FDA approval in late 2025, this once-daily pill offers a needle-free alternative to injections, demonstrating an average weight loss of up to 17% in clinical trials. With tiered pricing starting at $149 per month for self-pay patients, oral Wegovy is now available through major U.S. pharmacies and select telehealth platforms.
In a significant legal victory, Novo Nordisk announced on December 31, 2025, that China’s Supreme People’s Court had issued a final, positive ruling upholding the [Read More…]
Johnson & Johnson has finalized a landmark $3.05 billion acquisition of Halda Therapeutics, integrating the clinical-stage biotech’s proprietary RIPTACâ„¢ platform. This strategic move adds HLD-0915—a next-generation oral therapy for prostate cancer to J&J’s portfolio, signaling a major shift toward precision, “cell-killing” mechanisms designed to overcome traditional treatment resistance.
If 2024 was the year of “hype” for AI and GLP-1s, 2025 became the year of clinical delivery. We moved beyond the theoretical promise of [Read More…]
The FDA has officially approved the first-ever oral version of Wegovy, a once-daily tablet from Novo Nordisk. With clinical trials showing a 16.6% average weight loss, this landmark approval offers a needle-free alternative for obesity management and cardiovascular protection starting in January 2026.
The FDA has granted accelerated approval to Roche’s Lunsumio VELO™, a revolutionary subcutaneous formulation for adult patients with relapsed or refractory follicular lymphoma. By reducing administration time from several hours to just one minute, this CD20xCD3 bispecific antibody offers a more flexible, outpatient-friendly treatment option. Supported by a 75% objective response rate in heavily pre-treated patients, Lunsumio VELO marks a major shift toward patient-centered oncology care in 2025.
Major pharmaceutical leaders Novartis, Amgen, Gilead, GSK, and Sanofi have signed landmark voluntary agreements with the U.S. government to adopt “Most Favored Nation” pricing. The deal introduces the TrumpRx.gov platform for direct-to-patient savings, slashes prices for critical medications like insulin and Hep C cures, and triggers $150 billion in U.S. manufacturing investments.
In a potentially practice-changing development for oncology, Merck announced that its Phase 3 KEYNOTE-B15 trial (also known as EV-304) has met its primary and key [Read More…]
